CHMFL-48

• UNSPSC Description:

  CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC50 values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as STAT5 and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML)[1].

• Target Antigen:

  Apoptosis; Bcr-Abl; STAT

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/chmfl-48.html

• Smiles:

  CC1=C(N2C=C(C3=CN=C(NC=C4)C4=C3)C=N2)C=C(NC(C5=CC=C(CN6CCN(C)CC6)C(C(F)(F)F)=C5)=O)C=C1

• Molecular Weight:

  573.61

• References & Citations:

  [1]Lu T, et al. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Eur J Pharmacol. 2021 Apr 15;897:173944.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2479290-65-6